Microbicides research – free webinar

Gus Cairns
Published: 22 February 2013

As part of its European HIV prevention work, NAM is collaborating with AVAC to provide a series of webinars (conference calls with accompanying slides) to train and inform prevention advocates and anyone interested in the newest developments in HIV prevention technology.

The second webinar is entitled:

Microbicides research in Europe and beyond

Click here to register for the webinar and get phone numbers and joining instructions

This 90-minute webinar will examine the current state of research into topical microbicides – gels, lubes and devices that can be used to prevent HIV transmission during sex. It will provide advocates with an overview of global and European topical microbicide research. The presentations will be followed by a question and answer session with our expert speakers. The webinar will be conducted in English.

Time and date: 2pm UK time (GMT), Tuesday 26 February (3pm CET)

The webinar will feature presentations by:

  • Dr Sheena McCormack – Overview of topical microbicide research. Dr Sheena McCormack is Senior Clinical Scientist at the Clinical Trials Unit of the UK Medical Research Council. She is Principal Investigator of the Microbicides Development Programme, which ran the MDP 301 Phase III microbicide trial in four countries in sub-Saharan Africa, and of the recently started PROUD trial of Truvada pre-exposure prophylaxis in UK gay men.
  • Dr Charles Kelly – Outstanding research from the CHAARM microbicides research consortium. Dr Charles Kelly of King’s College, London is co-ordinator of the Combined Highly Active Anti-Retroviral Microbicides (CHAARM) programme, a collaborative project co-funded by the European Union under the 7th Framework Programme (FP7) for Research and Technological Development. CHAARM is a consortium of 31 partners representing 9 different countries in Europe including Ukraine, as well as South Africa and the US, with a €12m budget.
  • Jeremy Nuttall – Update on IPM’s pipeline: the dapivirine ring and beyond. Jeremy Nuttall is the Senior Director of Preclinical Sciences and Product Development for the International Partnership for Microbicides (IPM), where he is responsible for the preclinical testing of candidate microbicides and has broader product development responsibilities. Jeremy joined IPM in 2003 and has over 25 years of experience in drug development. Prior to IPM he worked as a toxicologist in contract research organisations and spent over 8 years in regulatory affairs at GlaxoSmithKline.
  • Harriet Langanke – Community advocacy for microbicides in Europe. Harriet Langanke is founder and director of GSSG: Gemeinnützige Stiftung Sexualität und Gesundheit, the German Foundation on sexuality and health. She is a journalist who has worked in the field of HIV and sexual health since 1991; she is also one of the co-founders of Germany’s national network Women and AIDS which celebrated its 20th anniversary last year. As an expert for HIV and STI prevention she works primarily for and with women.

The discussion will be introduced and moderated by Gus Cairns. Gus is a writer at NAM, where he edits HIV treatment update and Preventing HIV. He also edits the HIV prevention news: Europe bulletin as part of NAM’s programme of European prevention advocacy. He is a member of the European AIDS Treatment Group, co-chair of the Steering Committee of the PROUD PrEP trial, and a member of the steering committee of the Global Forum for MSM and HIV.

European advocates interested in learning more about microbicides research are encouraged to join this webinar and to email questions in advance to info@nam.org.uk. During the event, participants will be encouraged to ask questions via telephone.

To register for the webinar and get phone numbers and joining instructions: click this link

The following webinar, scheduled for 26 March, will examine the latest data on HIV treatment as prevention.

This project has been supported via a grant from Gilead Sciences Europe Ltd.

Gilead Sciences Europe Ltd has provided funding for this project and has had no editorial control over the content of the materials.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.